Lakefront Biotherapeutics NV

The latest quarter we hold for Lakefront Biotherapeutics NV

The quarter ending March 31, 2026, against the same quarter a year earlier.

These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.

Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.

Earnings calls

Lakefront Biotherapeutics NV has no earnings call transcript available.

What management said

“In June, we closed our acquisition of Ouro Medicines with Gilead. By combining the strengths of our teams, we expect to accelerate and expand the already rapid development of our lead asset, gamgertamig. To that end, in 2027, we look forward to adding new proof-of-concept basket studies of gamgertamig in additional autoimmune indications. We are pleased with the progress in our ongoing trials in the U.S. and abroad and the emerging clinical data we have seen reflecting durability in the initial data set and consistent responses from the most recent cohorts. We are excited by the potential for gamgertamig to represent an important new immune reset treatment approach for patients across a large number of conditions. We are looking forward to sharing additional data on this potential first-in-class, best-in-class T-cell engager later this year,”

Quoted verbatim from the release, and shown only when the filing attributes it to a named person.

What Lakefront Biotherapeutics NV does

This report contains information required under Belgian law. Lakefront Biotherapeutics NV is a limited liability company organized under the laws of Belgium, having its registered office at Schaliënhoevedreef 20T, 2800 Mechelen, Belgium and registered with the Crossroads Enterprise Database (RPR Antwerp – division Mechelen) under number 0466.460.429. Throughout this report, the term “Lakefront Biotherapeutics NV” refers solely to the non-consolidated Belgian company, and references to “we,” “our,” “the group” or “Lakefront” include Lakefront Biotherapeutics NV together with itssubsidiaries. This report is published in Dutch and in English. Lakefront will use reasonable efforts to ensure the translation and conformity between the Dutch and English versions. In case of inconsistency between the Dutch and the English version, the Dutch version shall prevail. Thisreport is available free of charge and upon request addressed to: Lakefront Biotherapeutics NV

The company’s own description, as it appears at the foot of the release.